FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 435 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 Glucose Control Key in Reducing Cancer Risk for People with Type... December 7, 2021 Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated... November 9, 2022 Patient Guide in Prostate Cancer Now Available in Vietnamese December 10, 2025 Load more HOT NEWS Today is Giving Tuesday Increase in Node-Positive and Stage III Breast Cancer After Two Months... Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma
